1. At a Glance
If there were an award for “Pharma Company That Quietly Doubles Profits Without a Bollywood-Style PR Campaign,” Syncom Formulations (India) Ltd would walk away with the trophy—and maybe dose the losers with a Vitamin D supplement.
Established in 1995, the Indore-based Syncom has evolved from a domestic generics maker to a globe-trotting pharma exporter across 25+ countries, juggling 500+ products in forms ranging from tablets to injectables to “how-did-we-even-make-this” ointments.
For Q2FY26 (ended September 2025), the company reported revenue of ₹12,666.95 lakh (₹126.67 crore) and PAT of ₹1,684 lakh (₹16.84 crore), with YoY sales growth of 19.7% and profit up 53.8%. Market cap now sits at ₹1,559 crore with a P/E of 24.8—because retail investors love cheap pharma stocks almost as much as Indians love “free consultation” WhatsApp forwards.
And yes, as per the Bhagavad Gita, “You have the right to perform your duty, but not the fruits of your action.” But tell that to Syncom shareholders—they’re clearly expecting a harvest, not a sermon.
2. Introduction
Once upon a time in Pithampur, Madhya Pradesh, there was a modest pharmaceutical firm that decided it could make drugs just as well as the big boys from Hyderabad and Mumbai. Fast-forward three decades, and Syncom Formulations is now an export-friendly generics player with a surprisingly balanced mix of business, geography, and drama.
The company does it all—tablets (48% of revenue), injectables (17%), capsules, ointments, and even some “trading of commodities” because why not? Diversification is the new detox.
What’s striking about Syncom’s recent journey isn’t just its 98% profit growth (TTM) or 58% sales growth—it’s how quietly the company scaled from ₹222 crore sales in FY23 to ₹513 crore in FY25 without a single over-the-top investor presentation filled with drone shots of factories.
But just when you thought this story was about boring efficiency, Syncom decided to add new acts: solar rooftop projects, nutraceutical expansions, real estate investments, and even amendments to its Memorandum of Association that could make it sound like half a conglomerate and half a start-up pitch deck.
So, what’s cooking in Indore’s pharma cauldron? Let’s decode the data capsule by capsule.
3. Business Model – WTF Do They Even Do?
Let’s put it simply—Syncom makes drugs you’ve probably never noticed but may have already consumed. They’re the unsung heroes of the generic world, supplying medicines that cure headaches for both patients and investors.
Here’s how it breaks down:
- Pharmaceutical Drug & Formulations: 88% of revenue — the core operation.
- Trading of Commodity: 11% — probably some side hustle because inflation isn’t kind.
- Renting of Property: 1% — passive income, baby.
The company runs two faces of business:
- Domestic (CRATUS Division): Works on Lifecare, Evolve (Women’s Health), and Nutrition (Vitamins & Supplements).
- International (Syncom Division): Exports across 25+ countries with 400+ registered products.
Production happens at its Pithampur facility—centrally located, logistically efficient, and expanded in 2023 to increase injectable capacity from 2 crore to 3 crore units annually (because the pandemic taught everyone that injectables are the new gold).
They’ve even diversified their MOA in 2025 to include power generation, nutraceuticals, and real estate, probably in case the pharma party
